Onconetix, Inc. Amortization of Debt Discount (Premium)
Onconetix, Inc. (ONCO) reported Amortization of Debt Discount (Premium) of $124.08 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-13
- Onconetix, Inc. amortization of debt discount (premium) for the quarter ending 2025-12-31 was $3.92K, a 22.83% decline year-over-year.
- Onconetix, Inc. amortization of debt discount (premium) for the quarter ending 2025-09-30 was $115.20K, a 44.68% increase year-over-year.
- Onconetix, Inc. amortization of debt discount (premium) for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Onconetix, Inc. amortization of debt discount (premium) for the quarter ending 2025-03-31 was $4.97K, a 97.29% decline year-over-year.
- Onconetix, Inc. amortization of debt discount (premium) for fiscal 2025 was $124.08K, a 67.06% decline from fiscal 2024.
- Onconetix, Inc. amortization of debt discount (premium) for fiscal 2024 was $376.66K, a 43.90% decline from fiscal 2023.
- Onconetix, Inc. amortization of debt discount (premium) for fiscal 2023 was $671.37K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.92K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $119.12K derived: sum of 2 quarters · filed 2026-03-13 | $119.12K derived: sum of 3 quarters · filed 2026-08-13 | $124.08K 10-K · filed 2026-03-13 |
| 2025-09-30 | $115.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $115.20K derived: sum of 2 quarters · filed 2026-08-13 | $120.16K 10-Q · filed 2025-11-13 | $125.24K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.97K 10-Q · filed 2026-08-13 | $10.05K derived: sum of 3 quarters · filed 2026-08-13 | $89.67K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $4.97K 10-Q · filed 2026-05-13 | $10.05K derived: sum of 2 quarters · filed 2026-05-13 | $89.67K derived: sum of 3 quarters · filed 2026-05-13 | $198.70K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $5.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $84.70K derived: sum of 2 quarters · filed 2026-03-13 | $193.73K derived: sum of 3 quarters · filed 2026-03-13 | $376.66K 10-K · filed 2026-03-13 |
| 2024-09-30 | $79.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $188.65K derived: sum of 2 quarters · filed 2025-11-13 | $371.58K 10-Q · filed 2025-11-13 | $559.86K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $109.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $291.96K 10-Q · filed 2025-08-14 | $480.24K derived: sum of 3 quarters · filed 2025-08-14 | $749.34K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $182.93K 10-Q · filed 2025-06-12 | $371.21K derived: sum of 2 quarters · filed 2025-06-12 | $640.30K derived: sum of 3 quarters · filed 2025-06-12 | |
| 2023-12-31 | $188.28K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $457.38K derived: sum of 2 quarters · filed 2025-06-02 | $671.37K 10-K · filed 2025-06-02 | |
| 2023-09-30 | $269.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-10 | $483.09K 10-Q · filed 2024-12-10 | ||
| 2023-06-30 | $214.00K 10-Q · filed 2023-10-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |